Table 1 Baseline clinical and laboratory characteristics
From: BK viruria and viremia in children with systemic lupus erythematosus
Clinical findings | At time of enrollment (N =32) |
|---|---|
Female (%) | 26 (81.3%) |
Age (years) | 16.0 |
Weight (kg) | 61.5 +/- 20.35 |
Ethnicity (%) | |
African American | 9 (28%) |
Caucasian | 12 (37.5%) |
Hispanic/Other | 11 (34.3%) |
Age at diagnosis of SLE (years) | 13.67 |
Age at enrollment (years) | 16.0 |
Duration of SLE (Months) | 22.9 +/- 20.51 |
New onset SLE (%) | 4 (12.5) |
Lupus nephritis WHO* (%) | |
I | 4 (12.5) |
II | 2 (6.3) |
III | 1 (3.1) |
III/V | 1 (3.1) |
IV | 11 (34.4) |
V | 4 (12.5) |
No renal biopsy | 9 (28.1) |
H/O antiphospholipid syndrome | 1 |
H/O neuropsychiatric manifestation/CNS Lupus | 6 |
H/O Vasculitis | 4 |
H/O Arthritis | 25 |
H/O Serositis | 3 |
H/O Pulmonary hemorrhage | 1 |
H/O Cytopenia | 22 |
H/O Raynaud’s phenomeonoN | 3 |
H/O Positive anti-double stranded DNA | 22 |
Positive ANA | 32 |
Ribonuceloprotein | 21 |
Laboratory findings | At time of enrollment [mean] |
Hemoglobin (g/dl) | 12.40 |
White blood counT (X 109/L) | 5.75 |
Platelet count (X 109/L) | 255 |
Serum creatinine (mg/dl) | 0.64 |
Complement 3 (g/dl) | 110 |
Complement 4 (g/dl) | 19 |
CD3 | 1004 |
CD19 | 0 |
IGG | 820 |
IGA | 128 |
IGM | 29 |
Urinalysis | |
Hematuria (%) | 5 (15.6) |
Proteinuria (%) | 6 (18.75) |
Normal (%) | 21 (65.6) |